Welcome to our dedicated page for CME Group SEC filings (Ticker: CME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the moving parts behind a global derivatives powerhouse can feel overwhelming. CME Group鈥檚 annual reports stretch past 200 pages, and its Form 4 insider notices drop without warning鈥攐ften right before rate-sensitive futures rallies. If you have ever asked, 鈥淲here can I find CME Group鈥檚 quarterly earnings report 10-Q filing?鈥� or 鈥淗ow do I decode clearinghouse risk in the 10-K?鈥�, you are not alone.
Stock Titan solves this complexity. Our AI-powered summaries turn dense disclosures into plain-English briefs鈥攕o understanding CME Group SEC documents with AI becomes routine. Need CME Group insider trading Form 4 transactions? We stream CME Group Form 4 insider transactions real-time, flagging executive stock transactions the moment they reach EDGAR. Looking for revenue per contract or margin requirements? The platform highlights them automatically within the CME Group annual report 10-K simplified, while our dashboard links every footnote to the relevant accounting rule.
You will find every filing type鈥�10-K, 10-Q, 8-K, DEF 14A, S-8鈥攊ndexed and searchable. Click the 10-Q tab for a concise CME Group earnings report filing analysis; open any 8-K for CME Group 8-K material events explained in seconds. The proxy section answers, 鈥淲hat鈥檚 inside the CME Group proxy statement executive compensation?鈥� by extracting pay ratio, incentive targets, and peer comparisons. AG真人官方-time alerts keep you ahead when material events hit or when directors buy shares. Whether you monitor fee trends, hedge fund positioning, or just want CME Group SEC filings explained simply, Stock Titan provides the clarity professionals need鈥攁ll in one place.
Sunil K. Cutinho, Chief Information Officer of CME Group Inc. (CME) reported two stock sale transactions on 08/26/2025. He sold 5,930 shares of CME Class A common stock at a weighted average price of $272.10 (prices ranged $271.69鈥�$272.58) and sold 5,966 shares at a weighted average price of $270.85 (prices ranged $270.32鈥�$271.21). The Form 4 shows the amount of Class A shares beneficially owned following the reported transactions as 23,406 shares on the first line and 17,440 shares on the second line. The filing was signed by an authorized representative for Mr. Cutinho and includes explanatory notes about aggregated sale prices.
Form 144 notice for CME Group, Inc. (CME) shows a proposed sale of 11,896 common shares valued at approximately $3,229,452.32, to be executed through Morgan Stanley Smith Barney on NASDAQ on 08/26/2025. The filer acquired the shares as performance shares (2,283 shares, acquired 03/15/2025) and restricted stock (9,613 shares, acquired 09/15/2020). No securities were reported sold in the past three months. The filing includes the standard representation that the seller is unaware of undisclosed material adverse information about the issuer.
CME Group Inc. (CME) Form 144 notice reports a proposed sale of 32,468 shares of Common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $200,054.83 and approximate sale date of 08/18/2025. The shares were acquired as restricted stock from the issuer on 05/02/2024 and were fully paid on that date. The filing lists 360,377,042 shares outstanding. Certain fields such as the identity or relationship of the selling person and the filing contact details are not populated in the provided text. The filer represents they are not aware of undisclosed material adverse information and affirms the signature and certification language required by Form 144.
CME Group director Patrick W. Maloney reported the acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Maloney now beneficially owns 4,098 shares directly. The filing indicates this was a planned acquisition under the company's director compensation program rather than an open market purchase.
- Transaction Code: A (Grant/Award)
- Ownership Form: Direct (D)
- Filing Type: Form 4 (Statement of Changes in Beneficial Ownership)
- Total Transaction Value: $145,251.96
CME Group director Harold Eugene Ford Jr. reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted pursuant to the CME Group Director Stock Plan.
Following this transaction, Ford's direct beneficial ownership increased to 2,091 shares. The Form 4 filing indicates this was a standard director compensation grant, demonstrating ongoing alignment between board member and shareholder interests.
- Transaction Type: Stock Award (Code A)
- Role: Director (Non-Employee)
- Filing Type: Individual
- Ownership: Direct
CME Group director Elizabeth A. Cook reported insider trading activity on June 25, 2025. The transaction involved the acquisition of 532 shares of Class A Common Stock at a price of $273.03 per share through a trust, granted pursuant to the CME Group Director Stock Plan.
Following the transaction, Cook's beneficial ownership includes:
- 18,771 shares held indirectly through a trust
- 20 shares held indirectly through a joint account
The Form 4 filing was signed by Jenelle Chalmers on behalf of Elizabeth A. Cook on June 26, 2025. This transaction represents a standard director compensation grant and demonstrates continued insider investment in the company.
CME Group director Timothy S. Bitsberger reported an insider transaction on Form 4 filed June 28, 2025, disclosing activity from June 25, 2025. Key details:
- Acquired 532 shares of Class A Common Stock at $273.03 per share
- Shares were granted through the CME Group Director Stock Plan
- Following the transaction, Bitsberger directly owns 11,121 shares
This transaction represents a standard director stock grant as part of CME Group's board compensation program. The filing was signed by Jenelle Chalmers on behalf of Bitsberger on June 26, 2025. No derivative securities were involved in this transaction.
CME Group director Rahael Seifu reported an acquisition of 532 shares of Class A Common Stock on June 25, 2025 at a price of $273.03 per share. The shares were granted through the CME Group Director Stock Plan.
Following this transaction, Seifu now beneficially owns 4,094 shares directly. The filing indicates this was a planned compensation grant rather than an open market purchase.
Key Transaction Details:
- Transaction Type: Stock Award (Plan-Based)
- Ownership Type: Direct
- Role: Director
- Total Transaction Value: $145,251.96
FAQ
What is the current stock price of CME Group (CME)?
What is the market cap of CME Group (CME)?
